ArticleOncoimmunology2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study.Journal of gastrointestinal cancer · 2020Trial
- Factors associated with immune‑related severe adverse events (Review).Molecular and clinical oncology · 2025Review
- Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.Discover oncology · 2022Article
- Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.Cancer immunology, immunotherapy : CII · 2022Article
- microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.Bioengineered · 2022Article
- High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.Journal of hematology & oncology · 2022Article
- PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.Journal of translational medicine · 2021Article
- Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.Journal for immunotherapy of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 20 institutions in 3 countries.
Alessio CortelliniMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.ORCID 0000-0002-1209-5735
Sebastiano ButiMedical Oncology, University Hospital of Parma, Parma, Italy.ORCID 0000-0003-0876-0226
Melissa BersanelliMedical Oncology, University Hospital of Parma, Parma, Italy.
Raffaele GiustiU.O.C. Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Rome, Italy.
Fabiana PerroneMedical Oncology, University Hospital of Parma, Parma, Italy.
Pietro Di MarinoClinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy.
Nicola TinariDepartment of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy.
Michele De TursiDepartment of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy.
Antonino GrassadoniaDepartment of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy.
Katia CannitaMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Alessandra TessitoreDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Federica ZorattoMedical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
Enzo VeltriMedical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
Francesco MalorgioMedical Oncology, "Santo Spirito" Hospital, Pescara, Italy.
Marco RussanoMedical Oncology, Campus Bio-Medico University, Rome, Italy.
Cecilia AnesiMedical Oncology, Campus Bio-Medico University, Rome, Italy.
Tea ZeppolaMedical Oncology, Campus Bio-Medico University, Rome, Italy.
Marco FilettiU.O.C. Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Rome, Italy.
Paolo MarchettiU.O.C. Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Rome, Italy.
Andrea BotticelliMedical Oncology, Sapienza University of Rome, Rome, Italy.
Gian Carlo Antonini CappelliniMedical Oncology, IDI-IRCCS, Roma, Italy.
Federica De GalitiisMedical Oncology, IDI-IRCCS, Roma, Italy.
Maria Giuseppa VitaleMedical Oncology, University Hospital of Modena, Modena, Italy.
Francesca RastelliMedical Oncology, Fermo Area Vasta 4, Fermo, Italy.
Federica PergolesiMedical Oncology, Fermo Area Vasta 4, Fermo, Italy.
Rossana BerardiOncology Clinic, Università Politecnica delle Marche, Ancona, Italy.
Silvia RinaldiOncology Clinic, Università Politecnica delle Marche, Ancona, Italy.
Marianna TudiniMedical Oncology, AV2 Fabriano ASUR Marche, Italy.
Rosa Rita SilvaMedical Oncology, AV2 Fabriano ASUR Marche, Italy.
Annagrazia PiredduMedical Oncology Unit, University Hospital of Cagliari, Cagliari, Italy.
Francesco AtzoriMedical Oncology Unit, University Hospital of Cagliari, Cagliari, Italy.
Daniela IaconoPulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, Italy.
Maria Rita MigliorinoPulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, Italy.
Alain GelibterMedical Oncology (B), Policlinico Umberto I, Rome, Italy.
Mario Alberto OcchipintiMedical Oncology (B), Policlinico Umberto I, Rome, Italy.
Francesco MartellaMedical Oncology, "G. Mazzini" Hospital, Teramo, Italy.
Alessandro InnoMedical Oncology Unit, IRCCS, Sacro Cuore Don Calabria Hospital, Verona, Italy.
Stefania GoriMedical Oncology Unit, IRCCS, Sacro Cuore Don Calabria Hospital, Verona, Italy.
Sergio BracardaMedical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy.
Cristina ZannoriMedical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy.
Claudia MosilloMedical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy.
Alessandro ParisiMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Giampiero PorzioMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Domenico MallardoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione "G. Pascale", Naples, Italy.
Maria Concetta FargnoliDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Marcello TiseoMedical Oncology, University Hospital of Parma, Parma, Italy.
Daniele SantiniMedical Oncology, Campus Bio-Medico University, Rome, Italy.
Paolo A AsciertoMelanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione "G. Pascale", Naples, Italy.ORCID 0000-0002-8322-475X
Corrado FicorellaMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
University of L'Aquila · ITUniversità Campus Bio-Medico · ITUniversity of Parma · ITAzienda Ospedaliera S.Maria · ITNini Hospital · LBPoliclinico Umberto I · ITUniversity of Chieti-Pescara · ITAzienda Ospedaliera Sant'Andrea · ITFerring Pharmaceuticals (Switzerland) · CHGoverno Italiano · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITMarche Polytechnic University · ITOspedale Sacro Cuore Don Calabria · ITOspedale Santa Maria Goretti · ITUniversity of Cagliari · ITOspedale di Santo Spirito · ITOspedale SS. Annunziata · ITSan Salvatore Hospital · ITSapienza University of Rome · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Agents, ImmunologicalNeoplasmsB7-H1 AntigenHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorRetrospective StudiesAntineoplastic Agents, ImmunologicalB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorDDR genesFamily history of cancerimmune checkpoint inhibitorsimmunotherapymultiple neoplasmsPD-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.